MARKET

HOWL

HOWL

Werewolf Therapeutics, Inc.
NASDAQ
0.6466
-0.4234
-39.57%
Pre Market: 0.6599 +0.0133 +2.06% 04:54 12/19 EST
OPEN
0.8000
PREV CLOSE
1.070
HIGH
0.8000
LOW
0.5588
VOLUME
1.40K
TURNOVER
0
52 WEEK HIGH
2.380
52 WEEK LOW
0.5588
MARKET CAP
31.39M
P/E (TTM)
-0.3993
1D
5D
1M
3M
1Y
5Y
1D
Clinical Momentum and Platform Validation Drive Undervalued Upside at Werewolf Therapeutics
TipRanks · 1h ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 18h ago
Werewolf Therapeutics Updates Pipeline and Outlines 2026 Priorities
TipRanks · 22h ago
Werewolf Therapeutics provides pipeline update, review of INDUKINE data
TipRanks · 22h ago
Werewolf Therapeutics announces 2025 priorities
TipRanks · 22h ago
WEREWOLF THERAPEUTICS INC - PLANS FOR TWO INDS BY MID-2027
Reuters · 22h ago
Werewolf Therapeutics Reports Promising Phase 1 Data for WTX-124 and WTX-330 in Advanced Cancer Trials
Reuters · 23h ago
Director Luke Evnin Reports Disposal of Werewolf Therapeutics Inc. Common Shares
Reuters · 1d ago
More
About HOWL
Werewolf Therapeutics, Inc. is a biopharmaceutical company engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. It is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. It is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Webull offers Werewolf Therapeutics Inc stock information, including NASDAQ: HOWL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOWL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOWL stock methods without spending real money on the virtual paper trading platform.